View Item 

Show simple item record

Optimal pathological response after neoadjuvant chemotherapy for muscle- invasive bladder cancer: results from a global, multicentre collaboration

dc.contributor.authorRavi, Praful
dc.contributor.authorPond, Gregory R.
dc.contributor.authorDiamantopoulos, Leonidas N.
dc.contributor.authorSu, Christopher
dc.contributor.authorAlva, Ajjai
dc.contributor.authorJain, Rohit K.
dc.contributor.authorSkelton, William P.
dc.contributor.authorGupta, Sumati
dc.contributor.authorTward, Jonathan D.
dc.contributor.authorOlson, Kathleen M.
dc.contributor.authorSingh, Parminder
dc.contributor.authorGrunewald, Camilla M.
dc.contributor.authorNiegisch, Guenter
dc.contributor.authorLee, Jae‐lyun
dc.contributor.authorGallina, Andrea
dc.contributor.authorBandini, Marco
dc.contributor.authorNecchi, Andrea
dc.contributor.authorMossanen, Matthew
dc.contributor.authorMcGregor, Bradley A.
dc.contributor.authorCurran, Catherine
dc.contributor.authorGrivas, Petros
dc.contributor.authorSonpavde, Guru P.
dc.date.accessioned2021-11-02T00:47:40Z
dc.date.available2022-12-01 20:47:39en
dc.date.available2021-11-02T00:47:40Z
dc.date.issued2021-11
dc.identifier.citationRavi, Praful; Pond, Gregory R.; Diamantopoulos, Leonidas N.; Su, Christopher; Alva, Ajjai; Jain, Rohit K.; Skelton, William P.; Gupta, Sumati; Tward, Jonathan D.; Olson, Kathleen M.; Singh, Parminder; Grunewald, Camilla M.; Niegisch, Guenter; Lee, Jae‐lyun ; Gallina, Andrea; Bandini, Marco; Necchi, Andrea; Mossanen, Matthew; McGregor, Bradley A.; Curran, Catherine; Grivas, Petros; Sonpavde, Guru P. (2021). "Optimal pathological response after neoadjuvant chemotherapy for muscle- invasive bladder cancer: results from a global, multicentre collaboration." BJU International (5): 607-614.
dc.identifier.issn1464-4096
dc.identifier.issn1464-410X
dc.identifier.urihttps://hdl.handle.net/2027.42/170883
dc.publisherWiley Periodicals, Inc.
dc.subject.otherpathological response
dc.subject.otherbladder cancer
dc.subject.otherneoadjuvant chemotherapy
dc.subject.otherrecurrence
dc.subject.other#BladderCancer
dc.subject.other#blcsm
dc.titleOptimal pathological response after neoadjuvant chemotherapy for muscle- invasive bladder cancer: results from a global, multicentre collaboration
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/170883/1/bju15434_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/170883/2/bju15434.pdf
dc.identifier.doi10.1111/bju.15434
dc.identifier.sourceBJU International
dc.identifier.citedreferenceWitjes JA, Bruins HM, Cathomas R et al. European association of urology guidelines on muscle- invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 2021; 79: 82 - 104
dc.identifier.citedreferenceAdvanced Bladder Cancer Meta- analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta- analysis of individual patient data advanced bladder cancer (ABC) meta- analysis collaboration. Eur Urol 2005; 48: 202 - 5
dc.identifier.citedreferenceGrossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859 - 66
dc.identifier.citedreferenceGriffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle- invasive bladder cancer: long- term results of the BA06 30894 trial. J Clin Oncol 2011; 29: 2171 - 7
dc.identifier.citedreferenceShariat SF, Karakiewicz PI, Palapattu GS et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006; 176 ( 6 Pt 1 ): 2414 - 22
dc.identifier.citedreferenceStein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long- term results in 1,054 patients. J Clin Oncol 2001; 19: 666 - 75
dc.identifier.citedreferenceSonpavde G, Goldman BH, Speights VO et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 2009; 115: 4104 - 9
dc.identifier.citedreferencePowles T, Kockx M, Rodriguez- Vida A et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med 2019; 25: 1706 - 14
dc.identifier.citedreferenceNecchi A, Raggi D, Gallina A et al. Updated results of PURE- 01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle- invasive bladder carcinoma with variant histologies. Eur Urol 2020; 77: 439 - 46
dc.identifier.citedreferenceChoi W, Porten S, Kim S et al. Identification of distinct basal and luminal subtypes of muscle- invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014; 25: 152 - 65
dc.identifier.citedreferencePlimack ER, Dunbrack RL, Brennan TA et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin- based chemotherapy in muscle- invasive bladder cancer. Eur Urol 2015; 68: 959 - 67
dc.identifier.citedreferenceVan Allen EM, Mouw KW, Kim P et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle- invasive urothelial carcinoma. Cancer Discov. 2014; 4: 1140 - 53
dc.identifier.citedreferenceHussain MA, Powles T, Albers P et al. IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high- risk muscle- invasive urothelial carcinoma (MIUC). J Clin Oncol 2020; 38 ( Suppl. ): 5000
dc.identifier.citedreferenceChoueiri TK, Jacobus S, Bellmunt J et al. Neoadjuvant dose- dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle- invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol 2014; 32: 1889 - 94
dc.identifier.citedreferenceZargar H, Zargar- Shoshtari K, Lotan Y et al. Final pathological stage after neoadjuvant chemotherapy and radical cystectomy for bladder cancer- does pT0 predict better survival than pTa/Tis/T1? J Urol 2016; 195: 886 - 93
dc.identifier.citedreferenceZargar H, Espiritu PN, Fairey AS et al. Multicenter assessment of neoadjuvant chemotherapy for muscle- invasive bladder cancer. Eur Urol 2015; 67: 241 - 9
dc.identifier.citedreferencePetrelli F, Coinu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta- analysis. Eur Urol 2014; 65: 350 - 7
dc.identifier.citedreferenceBray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394 - 424
dc.identifier.citedreferenceGschwend JE, Heck MM, Lehmann J et al. Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial. Eur Urol 2019; 75: 604 - 11
dc.identifier.citedreferenceParekh DJ, Reis IM, Castle EP et al. Robot- assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open- label, randomised, phase 3, non- inferiority trial. Lancet 2018; 391: 2525 - 36
dc.identifier.citedreferenceVasdev N, Zargar H, Noël JP et al. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. World J Urol 2019; 37: 165 - 72
dc.identifier.citedreferenceZargar H, Shah JB, van Rhijn BW et al. Neoadjuvant dose dense MVAC versus gemcitabine and cisplatin in patients with cT3- 4aN0M0 bladder cancer treated with radical cystectomy. J Urol 2018; 199: 1452 - 8
dc.identifier.citedreferencePeyton CC, Tang D, Reich RR et al. Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle- invasive bladder cancer. JAMA Oncol 2018; 4: 1535 - 42
dc.identifier.citedreferenceFlaig TW, Tangen CM, Daneshmand S et al. SWOG S1314: a randomized phase II study of co- expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle- invasive bladder cancer. J Clin Oncol 2019; 37 ( Suppl ): 4506.
dc.identifier.citedreferenceCuline S, Gravis G, Flechon A et al. Randomized phase III trial of dose- dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd- MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle invasive urothelial bladder cancer (MIUBC): preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses. J Clin Oncol 2020; 38 ( Suppl ): 437
dc.identifier.citedreferenceIyer G, Tully CM, Zabor EC et al. Neoadjuvant gemcitabine- cisplatin plus radical cystectomy- pelvic lymph node dissection for muscle- invasive bladder cancer: a 12- year experience. Clin Genitourin Cancer 2020; 18: 387 - 94
dc.identifier.citedreferenceYin M, Joshi M, Meijer RP et al. Neoadjuvant chemotherapy for muscle- invasive bladder cancer: a systematic review and two- step meta- analysis. Oncologist 2016; 21: 708 - 15
dc.identifier.citedreferenceYeshchina O, Badalato GM, Wosnitzer MS et al. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. Urology 2012; 79: 384 - 90
dc.identifier.citedreferenceFairey AS, Daneshmand S, Quinn D et al. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle- invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. Urol Oncol 2013; 31: 1737 - 43
dc.identifier.citedreferenceGalsky MD, Pal SK, Chowdhury S et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle- invasive bladder cancer. Cancer 2015; 121: 2586 - 93
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bju15434_am.pdf
Size:
325.3KB
Format:
PDF
View/Open
Name:
bju15434.pdf
Size:
462.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.